MedPharm Team

Paul joined MedPharm’s Board of Directors in 2018 and is currently an Operating Partner at Ampersand. Paul was previously the CEO and President of Renaissance Topicals Division and DPT Laboratories, which were both sold to Mylan in 2016. During his time at DPT, Paul was instrumental in the start-up and growth of Healthpoint Biologics, which sold to Smith & Nephew in 2011, and Coria, which sold to Valeant in 2008. Paul also spent time at Johnson & Johnson where he led an initiative to enter and expand operations in China. Paul holds a B.A. from the University of Texas at El Paso and an M.B.A from Southern Methodist University.

Eugene Ciolfi joined MedPharm as President and CEO in 2018. Specialising in sterile and non-sterile topical dosage forms, Gene brings with him over 25 years’ senior executive and technical experience in the CDMO and pharmaceutical sectors (including DPT, Bausch and Lomb Pharmaceuticals and Bio-Pharm Inc). During his time at DPT Laboratories he led the transformation of the Lakewood, NJ site into the Centre of Excellence for Sterile and Specialty Products, becoming one of the leading CDMO’s for sterile liquids, injectables, nasals and semi-solids. In 2016 Gene joined Torrent Pharmaceuticals as the Vice President and Site Head of US Operations.

Marc Brown co-founded MedPharm in August 1999. He has been the guiding force behind all of MedPharm’s scientific developments and intellectual property. He has been Professor of Pharmaceutics in the School of Pharmacy, University of Hertfordshire since 2006 and has visiting/honorary professorships at the Universities of Reading and King’s College London. He has over 200 publications and 26 patents describing his work. His research interests lie mainly in drug delivery to the skin, nail and airways. To date, he has been involved in the pharmaceutical development of over 55 products that are now on the market in Europe, America and Japan. Prior to MedPharm he was an academic in the Pharmacy Department at KCL.

Marc Brown co-founded MedPharm in August 1999. He has been the guiding force behind all of MedPharm’s scientific developments and intellectual property. He has been Professor of Pharmaceutics in the School of Pharmacy, University of Hertfordshire since 2006 and has visiting/honorary professorships at the Universities of Reading and King’s College London. He has over 200 publications and 26 patents describing his work. His research interests lie mainly in drug delivery to the skin, nail and airways. To date, he has been involved in the pharmaceutical development of over 55 products that are now on the market in Europe, America and Japan. Prior to MedPharm he was an academic in the Pharmacy Department at KCL.

Jon Lenn has direct responsibility for MedPharm’s operations in the United States based out of Durham, North Carolina. Since joining in 2015 he has led MedPharm’s development of cutting edge performance models for assessing penetration and activity of clients’ products targeted towards key biochemical pathways. He has over 15 years’ experience in developing dermatological projects with Connetics, Stiefel and GSK and has been directly involved with the development and approval of 8 products. He received his PhD on the topical delivery of macromolecules from the University of Reading.

Jon Lenn has direct responsibility for MedPharm’s operations in the United States based out of Durham, North Carolina. Since joining in 2015 he has led MedPharm’s development of cutting edge performance models for assessing penetration and activity of clients’ products targeted towards key biochemical pathways. He has over 15 years’ experience in developing dermatological projects with Connetics, Stiefel and GSK and has been directly involved with the development and approval of 8 products. He received his PhD on the topical delivery of macromolecules from the University of Reading.

David joins MedPharm with a wealth of experience leading financial operations for global and domestic organizations. This includes having roles of increasing responsibility at Corning, Reichhold, Research Triangle Institute and most recently at Mayne Pharma. David will be based in Durham and continue to focus the organization on continuous improvement over the finance function to ensure alignment with long term growth strategies. David has a Bachelor of Science from Worcester State University and an MBA in Business Administration from Bryant University. He is also a certified public accountant and a member of the American Institute of CPA’s.

Haydn initially joined MedPharm in 2012 as Quality Director before moving to Wales and establishing a Quality and Regulatory Consultancy in 2014. He has been involved in various consultative capacities throughout this time but re-joined MedPharm in September 2018. He directed the implementation of MedPharm’s new GMP compliant quality management system. He also designed and project managed manufacturing facility building works and subsequent MHRA licensing in Guildford, followed by MHRA MIA(IMP) license approval (2013). With his support, the facility received no major or critical GMP deficiencies during the 2017 MHRA inspection. His responsibilities include GLP, GMP, QA, QC and risk management. He has a background in analytical biochemistry and obtained his PhD in oligosaccharide-based receptor analogues for Vibrio Cholerae toxin at the School of Chemistry, Food & Pharmacy, University of Reading.

Marta joined MedPharm as Vice President of Quality Assurance in 2020. She brings with her over thirty years of diverse process and product experience in the biotech and pharmaceutical industry working in manufacturing, QC, Validation and QA areas. She has held leadership roles for companies like Cambrex, Abbott, MedImmune, DPT and most recently Torrent Pharma. Marta will be responsible for advancing the Quality Systems in the US for GLP and cGMP operations. Marta has a B.S in Chemical Engineering from the University of Puerto Rico, Mayaguez.

Lynn Allen joined MedPharm as VP of Business Development in 2019. Prior to joining MedPharm, Lynn worked in sales and management roles for DPT/Mylan and Jubilant Hollister-Stier. She has more than 25 years in sales, focusing on the contract services for sterile and non-sterile dosage forms. She is responsible for driving sales in North America for MedPharm. Lynn holds an MBA from University of Chicago.

Charles Evans has been with MedPharm for over 15 years and has been heavily involved in evolving and refining the company’s rigorous approach to formulation development. Charles has many years of expertise in the successful development of robust commercial products across all types of topical, inhalation and transdermal formulations. Moreover, he played a key role in the development of MedPharm’s proprietary MedSpray® technology that is currently under license to customers to enhance their products’ performance. He obtained his PhD at the University of Hertfordshire for the development of a novel dynamic spray formulation for the treatment of Athlete’s foot.

Charles Evans has been with MedPharm for over 15 years and has been heavily involved in evolving and refining the company’s rigorous approach to formulation development. Charles has many years of expertise in the successful development of robust commercial products across all types of topical, inhalation and transdermal formulations. Moreover, he played a key role in the development of MedPharm’s proprietary MedSpray® technology that is currently under license to customers to enhance their products’ performance. He obtained his PhD at the University of Hertfordshire for the development of a novel dynamic spray formulation for the treatment of Athlete’s foot.

Andrew McWaters joined MedPharm in 2019 and is the Vice President of Information Technology. His role is to advance MedPharm’s business processes and systems to ensure they are best positioned to support the company’s growth and expansion. Andrew joined MedPharm from BioBridge Global and worked previous with DPT Mylan and Lancer Corporation where he developed a strong track record of efficiency improving business processes and infrastructure. Andrew has a BSc in Information Technology from Wayland Baptist University and is a veteran of the United States Marine Corps with international experience, having served in Operation Desert Storm. Andrew brings with him a passion to help organizations innovate and automate.

Jessica Neil was one of the first employees at MedPharm’s site in Durham and has been key in many aspects of this site’s development. After leading the tissue culture department for many years, Jess is responsible for all the operations at MedPharm’s US site, based in Durham. She graduated with a degree in molecular genetics from the University of Cincinnati and went on to work in a wide range of scientific fields including obstetrics, neurology and cancer before entering the Center for Skin Biology at GlaxoSmithKline. At GSK she became immersed in everything to deal with the skin and has brought these skills to the leading topical formulation development CRO in the world.

Rob Turner was MedPharm’s first ever employee and was the creative force behind the development of many of MedPharm’s unique performance tests. These performance tests assess the activity of specific customer products in translatable ex vivo environments including the unique RoMarTM, TurChub® and ChubTur® systems for measuring product performance through nails. During Rob’s time at MedPharm, he has been responsible for running the Microbiology and Performance Testing departments in the UK as well as spending over 18 years as a Project Manager and managing this group for MedPharm, overseeing all research projects. Rob is now the General Manager of MedPharm, and responsible for all the operations at MedPharm’s UK site, based in Guildford. He has a background in topical drug delivery and microbiology and obtained his PhD in bio-adhesion and drug delivery at the School of Pharmacy, University of Portsmouth.

Andrew Muddle co-founded MedPharm in August 1999. He has spent over 25 years in pharmaceutical drug delivery in roles of increasing seniority. He has focused on ensuring that MedPharm’s commercial proposals meet customers’ expectations and overseeing the consistent and impressive growth of the company from its very beginnings. Prior to MedPharm, Andrew was Technical Director (Pharmaceutical Development) at PowderJect Pharmaceuticals plc where he was pivotal in its IPO in 1997.

David Parker is a General Partner of Ampersand Capital Partners, which he joined in 1994. Prior to Ampersand, David was a management consultant at Bain & Company and Mercer Consulting, and a corporate lender at First National Bank of Boston. Mr. Parker currently serves on the Boards of Directors of Bioventus, Detector Technologies, Gyros Protein Technologies and MedPharm. His prior Board Directorships have included Avista Pharma, ACLARA Biosciences, Assay Designs, NOVEX, Roadrunner Pharmacy and Signature Genomic Laboratories. David currently heads Ampersand’s European office, which is based in Amsterdam.

Trevor Wahlbrink is a Partner of Ampersand Capital Partners, which he joined in 2012. Prior to Ampersand, Mr. Wahlbrink was an investment banker at Morgan Keegan and Covington Associates where he advised on merger and acquisition and capital raising transactions for middle market healthcare and technology companies. Mr. Wahlbrink currently serves on the Boards of Directors of Confluent Medical and MedPharm. His prior Board Directorships have included Avista Pharma, Corpus Medical, Elite One Source Nutritional Services and ETE Medical. Mr. Wahlbrink is based in Ampersand’s Wellesley, MA USA offices.

Norman is an independent consultant with an extensive career in pharmaceutical research, contract manufacturing and development which included senior leadership roles at Patheon, Penn/PCI Pharmaceuticals and Lonza Biologics. He has over 30 years of experience in the pharmaceutical industry.

Clive Page is a member of the Scientific Advisory Committee at MedPharm and Professor of Pharmacology at King’s College London. He is Co-Founder and previous Chairman of the Board of Verona Pharma plc, a NASDAQ listed company developing new drugs for the treatment of respiratory diseases and has held Non-Executive Board positions at Stirling Products Ltd, Immune Regulation Ltd and Babraham Biotechnology Ltd. Mr Page was awarded an OBE for “Services to Pharmacology” in 2017 and currently serves as a Non-Executive Director of PreP Biopharma and as Non-Executive Chairman of the Board of EpiEndo.

Richard Guy received an M.A. in Chemistry from Oxford University, and his Ph.D. in Pharmaceutical Chemistry from the University of London. He has held academic posts at the University of California, San Francisco and the University of Geneva. In 2004, he joined the University of Bath as Professor of Pharmaceutical Sciences. Professor Guy’s research focuses on skin barrier function characterisation, topical and transdermal formulation development and optimisation, non-invasive biosensing and the prediction and assessment of skin penetration and topical bioavailability. He has published 380 peer-reviewed articles (H-index = 75; >21,000 citations) and 70 book chapters. He has co-authored one book and co-edited 7 others. He is also co-inventor of 12 patents. In 2016, Professor Guy was awarded the degree of Doctor of Science from the University of Oxford and the Maurice-Marie Janot Award from APGI for original and innovative research in pharmaceutics, biopharmaceutics and pharmaceutical technology. Having received the Founders’ Award of the Controlled Release Society (CRS) in 2013, Professor Guy was the first recipient of the CRS Transdermal Delivery Kydonieus Foundation Award in 2018. In that same year, he completed a year’s secondment at the European Medicines Agency as a National Expert in the area of regulatory science. Since 2013, research in Professor Guy’s laboratory has been funded continuously by grants from the US FDA.

Since completing his PhD in 1987 under the supervision of Professor Brian Barry, Adrian has worked in academia at the University of Bradford and more recently at Reading.  His research focusses on topical and transdermal drug delivery but his work on novel formulations and biomacromolecule delivery extends to mucosal tissue, ocular and oral routes.  He has published over 150 research articles ‪(Adrian Williams – ‪Google Scholar) alongside reviews, chapters and books – most recently  The Art and Science of Dermal Formulation Development – 1st Edition – (routledge.com) co-authored with MedPharm Co-Founder, Prof. Marc Brown.  In addition to numerous invited lectures at global academic conferences, he has been a member of advisory boards for various companies and acted as an expert witness in litigation matters in the UK, Europe and USA.